Medesis Pharma Revenue vs. Shares Outstanding
| ALMDP Stock | EUR 0.35 0.01 2.94% |
For Medesis Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Medesis Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Medesis Pharma SA utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Medesis Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Medesis Pharma SA over time as well as its relative position and ranking within its peers.
Medesis |
Medesis Pharma SA Shares Outstanding vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Medesis Pharma's current stock value. Our valuation model uses many indicators to compare Medesis Pharma value to that of its competitors to determine the firm's financial worth. Medesis Pharma SA is the top company in revenue category among its peers. It also is number one stock in shares outstanding category among its peers creating about 45.86 of Shares Outstanding per Revenue. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Medesis Pharma's earnings, one of the primary drivers of an investment's value.Medesis Revenue vs. Competition
Medesis Pharma SA is the top company in revenue category among its peers. Market size based on revenue of Biotechnology industry is presently estimated at about 43.47 Million. Medesis Pharma adds roughly 95,729 in revenue claiming only tiny portion of stocks in Biotechnology industry.
Medesis Shares Outstanding vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Medesis Pharma |
| = | 95.73 K |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Medesis Pharma |
| = | 4.39 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Medesis Shares Outstanding Comparison
Medesis Pharma is currently under evaluation in shares outstanding category among its peers.
Medesis Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Medesis Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Medesis Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Medesis Pharma's change in net profit over the period of time. It can combine multiple indicators of Medesis Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Medesis Pharma SA, a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs. The company was founded in 2003 and is based in Montpellier, France. MEDESIS PHARMA is traded on Paris Stock Exchange in France.
Medesis Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Medesis Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Medesis Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Medesis Pharma's important profitability drivers and their relationship over time.
Use Medesis Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medesis Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medesis Pharma will appreciate offsetting losses from the drop in the long position's value.Medesis Pharma Pair Trading
Medesis Pharma SA Pair Trading Analysis
The ability to find closely correlated positions to Medesis Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medesis Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medesis Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medesis Pharma SA to buy it.
The correlation of Medesis Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medesis Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medesis Pharma SA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medesis Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Medesis Pharma position
In addition to having Medesis Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Coal Thematic Idea Now
Coal
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Coal theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Coal Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Medesis Stock Analysis
When running Medesis Pharma's price analysis, check to measure Medesis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medesis Pharma is operating at the current time. Most of Medesis Pharma's value examination focuses on studying past and present price action to predict the probability of Medesis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medesis Pharma's price. Additionally, you may evaluate how the addition of Medesis Pharma to your portfolios can decrease your overall portfolio volatility.